Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pentoxifylline tablet controlled relasease tablet

A technology for theobromine controlled-release tablets and pentoxifylline, which is applied in the directions of drug delivery, cardiovascular system diseases, organic active ingredients, etc., can solve the problems of inconvenient medication, toxic side effects, irregular oral absorption, etc. The effect of increasing the number of times, improving the curative effect, and being convenient to carry

Inactive Publication Date: 2003-10-01
SHENYANG PHARMA UNIVERSITY
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] The existing pentoxifylline preparations have irregular oral absorption, rapid elimination in the body, inconvenient medication, and slight side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Tablets made by methods known in the pharmaceutical industry, containing the following components by weight percentage:

[0019] Pentoxifylline 25%

[0020] Sodium Chloride 55%

[0021] Gum Arabic 9.9%

[0022] Carbopol (carbomer) 10%

[0023] Magnesium Stearate 0.1%

[0024] Cellulose acetate 85%

[0025] PEG1500 15%

[0026] Acetone 90%

[0027] Absolute Ethanol 10%

[0028] Using film coating technology, pentoxifylline is made into a single-layer osmotic pump controlled-release tablet, and laser drilling or mechanical drilling is performed on one or both sides of the tablet to achieve the purpose of controlled release.

Embodiment 2

[0030] Tablets made by methods known in the pharmaceutical industry, containing the following components by weight percentage:

[0031] Pentoxifylline 45%

[0032] Lactose 30%

[0033] Mannitol 15%

[0034] Sodium Starch Carboxymethyl 12%

[0035] Sodium Lauryl Sulfate 11.9%

[0036] Magnesium Stearate 0.1%

[0037] Cellulose acetate 70%

[0038] PEG1500 30%

[0039] Acetone 90%

[0040] Absolute Ethanol 10%

[0041] Using film coating technology, pentoxifylline is made into a single-layer osmotic pump controlled-release tablet, and laser drilling or mechanical drilling is performed on one or both sides of the tablet to achieve the purpose of controlled release.

Embodiment 3

[0043] Tablets made by methods known in the pharmaceutical industry, containing the following components by weight percentage:

[0044] Pentoxifylline 45%

[0045] Lactose 45%

[0046] Low Substituted Hydroxypropyl Cellulose 8%

[0047] Tween 80 1.9%

[0048] Magnesium Stearate 0.1%

[0049] Hydroxypropyl Methyl Cellulose 20%

[0050] Ethyl Cellulose 70%

[0051] Triethyl Citrate 10%

[0052] Ethanol 50%

[0053] Dichloromethane 50%

[0054] Using film coating technology, pentoxifylline is made into a single-layer osmotic pump controlled-release tablet, and laser drilling is performed on one or both sides of the tablet to achieve the purpose of controlled release.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to View More

Abstract

A slow-releasing torental table for treating peripheral obliteration vasculitis, sequelae of arteriosclerosis, and local ischemia is prepared from torental (20-70 wt.%), slow releasing agent (cellulose acetate and / or ethyl cellulose) (30-80 wt.%), and other assistants. Its advantages are high curative effect, durable action and low by-effect.

Description

Technical field: [0001] The present invention relates to a blood rheology improving agent, which is mainly used for treating peripheral vasculitis obliterans, sequelae of cerebral arteriosclerosis, local ischemia and other cerebrovascular disorders and vascular headache, specifically a kind of pentoxifylline Controlled release tablets. Background technique: [0002] The existing pentoxifylline preparations have irregular oral absorption, rapid elimination in the body, inconvenient administration, and mild side effects. Chinese Patent No.: 92109413 discloses an invention patent named "Method for preparing chlorohexanone", which is a method for preparing pentoxifylline. Invention content: [0003] The object of the present invention is to provide a pentoxifylline controlled-release tablet which maintains effective blood drug concentration within one day in the body, improves curative effect and reduces toxic and side effects. [0004] The purpose of the present invention i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K31/529A61P9/14A61P25/04
Inventor 潘卫三胡建平
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com